

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Gessica Filocamo *et al.*

**Serial No.:** 10/586,701                      Case No.: ITR0064YP

**Filed:** July 20, 2006

**For:** INHIBITORS OF MAMMALIAN HDAC11 USEFUL  
FOR TREATING HDAC 11 MEDIATED DISORDERS

**Art Unit:**  
To be assigned

**Examiner:**  
To be assigned

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**Communication**

Sir:

This is responsive to a Notification of Defective Response dated June 10, 2009, a response to which is due by July 10, 2009.

**Remarks** begin on page 2 of this paper.

### REMARKS

The instant Response was re-mailed by the P.T.O due to incomplete response dated May 27, 2009.

A copy of Applicants response to the previous mailing is attached as a response to the instant Notice. No new matter is added.

Any fees that may be due in connection with the filing of this paper of application may be charged to Deposit Account No. 13-2755. If the Examiner believes that a telephone conference would be of value, he is requested to call the undersigned counsel at the number listed below.

Respectfully submitted,

By /Vineet Kohli, Reg. No. 37,003/

Vineet Kohli  
Registration No. 37,003  
Attorney for Applicants

Merck & Co., Inc.  
PO Box 2000 - RY 60-30  
Rahway, New Jersey 07065-0907  
Telephone No. (732) 594-3889

Date: June 29, 2009

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants:** Gessica Filocamo *et al.***Serial No.:** 10/586,701**Case No.:** ITR0064YP**Filed:** July 20, 2006**For:** INHIBITORS OF MAMMALIAN HDAC11 USEFUL  
FOR TREATING HDAC 11 MEDIATED DISORDERS**Art Unit:**

To be assigned

**Examiner:**

To be assigned

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Dear Sirs:

In response to the Notification of Defective Response mailed May 27, 2009, for which a response is due by June 27, 2009, and in compliance with 37 C.F.R. 1.821(f) of the Rules of Practice in Patent Cases: Application Disclosures Containing Nucleotide And/OR Amino Acid Sequences, the signature page and following statements are being submitted herewith.

The sequence listing of the present invention is being submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file name ITR0064YP-SEQTXT-16JUN2009", creation date 06/16/2009, and a size of 8,837 bytes. Also submitted is a new paper copy sequence listing labeled "ITR0064YP-SEQLIST-16JUN2009".

Applicants believe no additional fees are due but the Commissioner is authorized to charge any fees in connection with this response to Merck Deposit Account No. 13-2755.

Respectfully submitted,

By /Vineet Kohli, Reg. No. 37003/  
Vineet Kohli  
Registration No. 37,003  
Attorney for Applicants

Merck & Co., Inc.  
PO Box 2000 - RY 60-30  
Rahway, New Jersey 07065-0907  
Telephone No. (732) 594-3889

Date: June 16, 2009